Journal Watch · Science Advances · 2026

Targeting LOXL4-driven matrix stiffening with acetyldigoxin restores CD8<sup>+</sup> T cell function in lung cancer.

Repurposing acetyldigoxin as a LOXL4-targeted therapy offers a promising clinical strategy to overcome ECM-mediated immunotherapy resistance in lung cancer.

Gu X, Zhu Y, Xu L et al.Science Advances3 min readPharma relevance 70/100

DOI: 10.1126/sciadv.aef1694PMID: 42726857Study type: preclinical (animal / model) study

TL;DR

Repurposing acetyldigoxin as a LOXL4-targeted therapy offers a promising clinical strategy to overcome ECM-mediated immunotherapy resistance in lung cancer.

Key findings

  • Acetyldigoxin was identified as a high-affinity LOXL4 inhibitor.
  • It softened the ECM, disrupted the mechanosignaling-epigenetic axis, reversed CD8<sup>+</sup> T cell exhaustion, and synergized with anti-PD-1 blockade to achieve durable tumor regression.
  • In conclusion, this study uncovers a mechanotransduction-to-epigenetic pathway where LOXL4-driven matrix stiffening induces CD8<sup>+</sup> T cell exhaustion.
  • Repurposing acetyldigoxin as a LOXL4-targeted therapy offers a promising clinical strategy to overcome ECM-mediated immunotherapy resistance in lung cancer.

What they did

Molecular docking was performed to explore Food and Drug Administration-approved agents targeting LOXL4. The results demonstrated that tumor-derived LOXL4 stiffened the ECM, which activates the mechanosensor Piezo1 in CD8<sup>+</sup> T cells, triggering Ca<sup>2+</sup> influx and downstream FAK1-YAP1 signaling. Nuclear YAP1 transactivated YBX1, which recruited the metabolic enzyme ACLY and the histone acetyltransferase KAT2A to exhaustion gene loci, epigenetically reinforcing terminal exhaustion. Conditional knockout of <i>Piezo1</i>, <i>Ybx1</i>, <i>Acly</i>, and <i>Kat2a</i> in murine CD8<sup>+</sup> T cells abolished stiffness-induced exhaustion and suppressed tumor growth.

Full abstract (original)

Background: Extracellular matrix (ECM) stiffness is known to impair T cell function, yet the underpinning molecular cascade remains undefined. This paper investigates the role of lysyl oxidase-like 4 (LOXL4) in ECM stiffening and CD8<sup>+</sup> T cell function in lung cancer. <i>Loxl4</i> knockout and mouse recombinant LOXL4 protein systems, along with <i>Piezo1</i>, <i>Ybx1</i>, <i>Acly</i>, and <i>Kat2a</i> conditional knockout mouse models were established. ECM stiffness was measured by atomic force microscopy, and T cell exhaustion markers were analyzed using flow cytometry. RNA sequencing, ATAC-seq, CUT&Tag, chromatin immunoprecipitation-quantitative polymerase chain reaction, and luciferase assays were used to explore the underlying molecular mechanisms.

What they did: Molecular docking was performed to explore Food and Drug Administration-approved agents targeting LOXL4. The results demonstrated that tumor-derived LOXL4 stiffened the ECM, which activates the mechanosensor Piezo1 in CD8<sup>+</sup> T cells, triggering Ca<sup>2+</sup> influx and downstream FAK1-YAP1 signaling. Nuclear YAP1 transactivated YBX1, which recruited the metabolic enzyme ACLY and the histone acetyltransferase KAT2A to exhaustion gene loci, epigenetically reinforcing terminal exhaustion. Conditional knockout of <i>Piezo1</i>, <i>Ybx1</i>, <i>Acly</i>, and <i>Kat2a</i> in murine CD8<sup>+</sup> T cells abolished stiffness-induced exhaustion and suppressed tumor growth.

Results & conclusions: Acetyldigoxin was identified as a high-affinity LOXL4 inhibitor. It softened the ECM, disrupted the mechanosignaling-epigenetic axis, reversed CD8<sup>+</sup> T cell exhaustion, and synergized with anti-PD-1 blockade to achieve durable tumor regression. In conclusion, this study uncovers a mechanotransduction-to-epigenetic pathway where LOXL4-driven matrix stiffening induces CD8<sup>+</sup> T cell exhaustion. Repurposing acetyldigoxin as a LOXL4-targeted therapy offers a promising clinical strategy to overcome ECM-mediated immunotherapy resistance in lung cancer.

Abstract © the authors / Science Advances (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1126/sciadv.aef1694 · PubMed 42726857.

Why it matters for pharma & biotech

  • Directly relevant to teams in targeted oncology / immuno-oncology, small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: targeted oncology / immuno-oncology · small-molecule drug discovery

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Science Advances study find?

Repurposing acetyldigoxin as a LOXL4-targeted therapy offers a promising clinical strategy to overcome ECM-mediated immunotherapy resistance in lung cancer.

What type of study is this?

It is a preclinical (animal / model) study, published in Science Advances in 2026. Molecular docking was performed to explore Food and Drug Administration-approved agents targeting LOXL4.

Where can I read the original paper?

The original is at the publisher via DOI 10.1126/sciadv.aef1694. PubMed ID: 42726857. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Gu X, Zhu Y, Xu L et al.. Targeting LOXL4-driven matrix stiffening with acetyldigoxin restores CD8&lt;sup&gt;+&lt;/sup&gt; T cell function in lung cancer.. Science Advances (2026). DOI: 10.1126/sciadv.aef1694.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/targeting-loxl4-driven-matrix-stiffening-with-acetyldigoxin-restores-cd8-ef1694/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides